Phibro Animal Health Corp. (PAHC)
38.37
+0.63
(+1.67%)
USD |
NASDAQ |
Sep 01, 16:00
38.03
-0.34
(-0.89%)
After-Hours: 07:50
Phibro Animal Health Research and Development Expense (Annual) : 24.55M for June 30, 2026
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| June 30, 2026 | 24.55M |
| June 30, 2025 | 23.73M |
| June 30, 2024 | 29.19M |
| June 30, 2023 | 24.40M |
| June 30, 2022 | 20.83M |
| June 30, 2021 | 17.76M |
| June 30, 2020 | 13.74M |
| June 30, 2019 | 12.08M |
| Date | Value |
|---|---|
| June 30, 2018 | 9.998M |
| June 30, 2017 | 9.442M |
| June 30, 2016 | 11.03M |
| June 30, 2015 | 9.511M |
| June 30, 2014 | 8.212M |
| June 30, 2013 | 6.638M |
| June 30, 2012 | 7.189M |
| June 30, 2011 | 6.807M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Zoetis, Inc. | 698.00M |
| Merck & Co., Inc. | 12.51B |
| ANI Pharmaceuticals, Inc. | 51.66M |
| Corcept Therapeutics, Inc. | 254.91M |
| Veru, Inc. | 15.59M |